Evolent Health (EVH)
(Delayed Data from NYSE)
$31.98 USD
+0.12 (0.38%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $31.99 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.98 USD
+0.12 (0.38%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $31.99 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Phunware (PHUN) Surges: Stock Moves 9.9% Higher
by Zacks Equity Research
Phunware (PHUN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Will Evolent Health (EVH) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
eGain (EGAN) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
eGain (EGAN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Evolent Health (EVH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 70.00% and -1.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Chegg (CHGG) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Benefits from remote learning and rising subscribers are likely to get reflected in Chegg's (CHGG) Q2 performance.
Evolent Health (EVH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Evolent Health (EVH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Evolent Health (EVH) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evolent Health (EVH) stock based on the movements in the options market lately.
Will Evolent Health (EVH) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent Health (EVH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of -75.00% and 1.47%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Company News for Nov 29, 2019
by Zacks Equity Research
Companies In The News Are: CENT, BOX, DPLO, EVH
Options Traders Expect Huge Moves in Evolent Health (EVH) Stock
by Zacks Equity Research
Investors need to pay close attention to Evolent Health (EVH) stock based on the movements in the options market lately.
Evolent Health (EVH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 40.00% and 1.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Evolent Health (EVH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Evolent Health (EVH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolent Health (EVH) stock based on the movements in the options market lately.
Evolent Health (EVH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of -13.04% and -0.19%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent Health (EVH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 8.82% and 2.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Evolent Health (EVH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent Health (EVH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of -75.00% and 2.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Evolent Health (EVH) Looks Good: Stock Adds 6.4% in Session
by Zacks Equity Research
Evolent Health (EVH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Why Evolent Health (EVH) Isn't Done Growing Earnings Yet
by Zacks Equity Research
Evolent Health (EVH) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Evolent Health (EVH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 20.00% and 5.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Evolent Health (EVH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Evolent Health (EVH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent Health (EVH) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Evolent Health (EVH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Evolent Health (EVH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 25.00% and 1.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?